ERBB2 and breast cancer: In addition to the promising efficacy in HER2-positive breast cancer, use of lapatinib in HER2-negative diseases, especially in triple-negative cancers due to its frequent EGFR overexpression, is of interest and being tested currently [21, 22] but has been found to elicit diverse effects in different subgroups [8, 14, 39, 40].